Search results
Results from the WOW.Com Content Network
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. [4] For active tuberculosis, it is often used together with rifampicin , pyrazinamide , and either streptomycin or ethambutol . [ 5 ]
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
Ethambutol/isoniazid is a fixed-dose combination medication used to treat tuberculosis. [1] It is a fixed dose combination of ethambutol and isoniazid. [1] It is used along with other antituberculosis medication. [1] It is taken by mouth. [1] Side effects are those of the underlying medications. [1]
Treatment courses are a minimum of 18 months and may last years; it may require surgery, though death rates remain high despite optimal treatment. That said, good outcomes are still possible. Treatment courses that are at least 18 months long and which have a directly observed component can increase cure rates to 69%. [91] [92]
At age 70, that includes her wine, though, yeah, she’s up on the risks. “When the doctor asks, ‘How many glasses a day?,’ I totally tell the truth, so I sound like a blatant alcoholic ...
After Melanie Duquette, 70, had extensive back surgery earlier this year, her doctor sent her to a rehab center to recover since it wasn’t safe for her to be home alone.
Merck said its drug met the main goal of significantly reducing the time to disease worsening, lung transplantation or death in a late-stage study of 172 patients with advanced stages of the ...
For those started on treatment for multidrug-resistant TB 56% successfully completed treatment, either treatment course completion or eradication of disease; 15% of those died while in treatment; 15% were lost to follow-up; 8% had treatment failure and there was no data on the remaining 6%.